Synapse - Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence

Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence Meeting Abstract

Authors:	Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; Abramson, J. S.; Batlevi, C. L.; Matasar, M. J.; Noy, A.; Owens, C.; Palomba, M. L.; Kumar, A.; Takvorian, T.; Ni, A.; Choma, M.; Friedman, C.; Chadha, P.; Simkins, E.; Ruiters, J.; Sechio, S.; Portman, D.; Nolet, N.; Mahajan, N.; Martignetti, R.; Mi, J.; Scorsune, K. J.; Lynch, J. M.; McGree, B.; Hughes, S. Y.; Grieve, C.; Roeker, L. E.; Thompson, M. C.; Johnson, P. C.; Roshal, M.; Huang, J.; Biondo, J. M. L.; Wu, J. Q.; Jacob, A. P.; Abdel-Wahab, O.; Zelenetz, A. D.
Abstract Title:	Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
Meeting Title:	63rd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	138
Issue:	Suppl. 1
Meeting Dates:	2021 Dec 11-14
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2021-11-23
Language:	English
ACCESSION:	WOS:000736413907095
DOI:	10.1182/blood-2021-150961
PROVIDER:	wos
Notes:	Meeting Abstract: 3753 -- Hybrid meeting, also took place online -- Stephanie N. Hughes' middle initial is incorrectly listed as "Y." by publisher -- Source: Wos